Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1994-10-26
1997-03-11
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
4242041, 424497, 424422, 424451, 424464, 424482, 4242061, 4242261, 4242121, 4242331, 4242191, 4242691, A61K 3900, A61K 916, A61K 1300, A61K 3912
Patent
active
056098715
ABSTRACT:
An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating composition. The microcapsules are orally administered. The coating protects the protein as it passes through the stomach. Upon reaching the small intestines, the basic pH of the intestinal juices will dissolve the coating, allowing the protein to be released and induce antigen specific immune response which has the specificity of the native molecule. The stabilizing agent protects the therapeutic protein from denaturation during the encapsulation process.
REFERENCES:
patent: 4016254 (1977-04-01), Seager et al.
patent: 4017647 (1977-04-01), Ohno et al.
patent: 4348384 (1982-09-01), Horikoshi et al.
patent: 4469677 (1984-09-01), Michael et al.
patent: 4507276 (1985-03-01), Tencza et al.
patent: 4642232 (1987-02-01), Yman et al.
patent: 4704295 (1987-11-01), Porter et al.
patent: 4798844 (1989-01-01), Fujita et al.
patent: 4820627 (1989-04-01), McGeehan et al.
patent: 4874613 (1989-10-01), Hsiao et al.
patent: 4900557 (1989-10-01), Dell et al.
patent: 4920209 (1990-04-01), Davis et al.
patent: 4946945 (1990-08-01), Wojdani
patent: 4981693 (1991-01-01), Higashi et al.
patent: 4996058 (1991-02-01), Sinnreich et al.
patent: 5049390 (1991-09-01), Wojdani
patent: 5171568 (1992-12-01), Burke et al.
patent: 5202159 (1993-04-01), Chen et al.
patent: 5230888 (1993-07-01), Baltimore et al.
patent: 5236713 (1993-08-01), Wato et al.
patent: 5286493 (1994-02-01), Oshlack
Wong, George K., Development of Novel Oral Enteric-Coated Aquaculture Vigro Vaccines (1990) (unpublished Ph.D. thesis, Oregon State University, available from UMI Dissertation Services).
Moldoveanu et al., 1993. J. Infect. Disease 167:84-90.
Wheeler et al., 1987. Int. Arch. Allergy Appl. Immunol. 83(4):354-8.
Lai, 1985. Diss. Abs. Int. 49(10B):4254.
Waldman et al., 1986. Amer. J. Med. Sci. 292(6):367-71.
Fukumori, et al., 1988(a). Chem. Pharm. Bull. 36(12):4927-32.
Fukumori, et al., 1988. Chem. Pharm. Bull. 36(8):3070-78.
Wong, 1990. Diss. Abs. Int. 52(5B):2519.
Langer, et al., 1990. Science 249:1527-1533.
Murray, et al., 1990. Aus. J. Hospital Pharm. 20(3):235-38.
Chanock et al. (1966), Immunization by selective infection with Type 4 adenovirus grown in human diploid tissue culture, JAMA 195(6):151-158.
O'Hagan, T. O. (1994), Oral immunization and the common mucosal immune system, CRC Press, Inc. 1-24.
Moldoveanu et al. (1993), Oral immunization with influenza virus in biodegradable micorspheres, J. Infect. Dis. 84-86.
Czerkinsky et al. (1993), Induction and assessment of immunity at enteromucosal surfaces in humans: Implications for vaccine development Clin. Infect. Dis. S106-113.
Manganaro et al. (1994), Oral immunization: Turning fantasy into reality, Int. Arch Allergy Immunol. 103:223-233.
Michael, J. (1989), The role of digestive enzymes in orally induced immune tolerance, Immunogical Invest 18:1049-1054.
Wheeler et al. 1987. Immunogenicity in guinea pigs and tolerance in grass . . . Int. Arch. Allergy Appl. Immunol. 83(4):354-8.
Lai. 1985. Design and evaluation of water based pseudo-latex enteinc coating systems. Diss. Abs. Int. 49(10B):4254.
Waldman et al. 1986. Secretory Antibody following oral influenza immunization. Am. J. Med. Sci. 292(6):367-71.
Alonso, M. J. et al. (Dept. of Chem. Eng., MIT), Controlled Release of Tetanus Toxoid From Poly(Lactic/Glycolic Acid) Microspheres, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 19 (1992), Controlled Release Society, Inc., pp. 122-123.
Excerpts from Structure and Development of the Immune System, Chapter 2, pp. 29, 30-31.
Gilligan, C. A. et al., Oral Vaccines: Design and Delivery, Int'l Journal of Pharmaceutics, 75 (1991) pp. 1-24.
Moldoveanu, Zina et al., Oral Immunization with Influenza Virus Biodegradable Microspheres, The Journal of Infectious Diseases, vol. 167, No. 1, Jan. 1993, pp. 84-90.
Novak, Miroslav et al., Murine model for evaluation of protective immunity to influenza virus (6 pages).
O'Hagan, D. T. et al. (Dept. of Pharmaceutical Sciences, Un. of Nottingham), Biodegradable Microparticles as Oral Vaccines, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 19 (1992), Controlled Release Society, Inc., pp. 118-119.
Tamura, Shin-ichi, et al., Superior Cross-Protective Effect of Nasal Vaccination to Subcutaneous Inoculation with Influenza Hemagglutinin Vaccine, Eur. J. Immunol. 1992. 22: 447-481.
Waldman, Robert H., et al., AgE-Dependent Antibody Response in Mice and Humans Following Oral Influenza Immunization, Journal of Clinical Immjnology, vol. 7, No. 4, 1987, pp. 327-332.
Wilson, A. D. et al., Adjuvant Action of Chloera Toxin and Pertussis Toxin in the induction of IgA Antibody Response to Orally Administered Antigen (6 pages).
Xu-Amano, Jiangchun, et al., Selective Induction of Th2 cells in murine Peyer's Patches by Oral Immunization, International Immunology, vol. 4, No. 4, pp. 433-445.
Eldridge, JH et al., 1990, Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microcapsules target to the Peyer's patches. J. Controlled Release 11:205-214.
O'Hagan, DT, et al., 1991, Biodegradable microparticle as controlled release antigen delivery systems. Immunology 73:239-242.
Davis et al., Microbiology, Third Edition, Chapter 67, p. 1270 (1980).
Litwin Allen
Michael J. Gabriel
Housel James C.
Minnifield N. M.
LandOfFree
Oral administration of therapeutic proteins for treatment of inf does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral administration of therapeutic proteins for treatment of inf, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral administration of therapeutic proteins for treatment of inf will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-441326